Harbor Health Care ETF Q2 2026 Commentary

Harbor Capital Advisors 79 Followers Follow Summary Health Care sentiment shifted meaningfully during the second quarter of 2026. During the second quarter, the Harbor Health Care ETF (“ETF”) returned 15.30%. Biotechnology was the largest contributor to relative performance during the quarter, with strong stock specific returns from several holdings, driven by clinical data catalysts and M&A activity. Pharma was the largest detractor from relative performance, driven by our underweight exposure to Eli Lilly, the benchmark's largest constituent by a wide margin. Heading into the third quarter, we see the M&A backdrop for biopharma as even more favorable than it was earlier in the year. LeoWolfert/iStock via Getty Images Heading into the third quarter, we see the M&A backdrop for biopharma as even more favorable than it was earlier in the year. - Westfield Capital Management Company, L.P. Market in Review Health Care sentiment This article was written by Harbor Capital Advisors 79 Followers Follow Harbor Capital is an asset manager focused on curating an intentionally select suite of active ETFs that they believe have the potential to produce compelling, risk-adjusted returns within a portfolio. Note: This account is not managed or monitored by Harbor Capital, and any messages sent via Seeking Alpha will not receive a response. For inquiries or communication, please use Harbor Capital's official channels.